Infections by multidrug resistant organisms (MDROs) are a global health threat with a worrying increasing trend. In fragile ...

Aztreonam–avibactam is a promising treatment for complicated intra-abdominal infections and hospital-acquired or ...

It's the first and only such therapy approved to fight antimicrobial resistance, or AMR, in bacterial infections.

LpxC inhibitors are emerging as a promising class of antibiotics targeting Gram-negative bacteria, which are notorious for their resistance to many existing antibiotics. LpxC, an essential enzyme ...

AbbVie has announced that the U.S. Food and Drug Administration (FDA) has approved EMBLAVEO (aztreonam and avibactam), as a ...

AbbVie said on Friday that the U.S. Food and Drug Administration approved its drug for complicated intra-abdominal infections ...

The FDA has approved the intravenous antibiotic Emblaveo for adults with complicated intra-abdominal infections who have limited treatment options.

The final peptide concentration range was 4 to 1024 μg/mL. The positive control was cells treated with 0.1% Triton-X100, the negative controls were cells only, and the sterility control was media only ...

All patients with suspected Gram-negative endocarditis should undergo transesophageal echocardiography (TEE) to confirm the diagnosis and assess for cardiac complications such as intracardiac ...

NORTH CHICAGO, Ill. - The U.S. Food and Drug Administration (FDA) has approved EMBLAVEO™ (aztreonam and avibactam) for the ...

Early detection and public health interventions are critical to improve sepsis survival rates and limit its long-term ...